Brief Report: Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology Model
Preprint from Research Square, 22 Dec 2021
Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors
Published in CPT Pharmacometrics Systems Pharmacology, December 1, 2021
Using Modeling for Dose Recommendations of A Novel Drug for Urea Cycle Disorders
Presented by Acer Therapeutics and Rosa at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) meeting, November 2021
Surrogate Modeling with Machine Learning for Faster Virtual Patient Cohort Generation in QSP Models.
Presented by Rosa at the American Conference on Pharmacometrics (ACoP), November 2021
Reuse of a published model with fasting data from a novel drug formulation for a rare disorder
Presented by Acer Therapeutics and Rosa at the Population Approach Group in Europe (PAGE) meeting, September 2021
Development of a systemic lupus erythematosus (SLE) QSP model linking systemic biomarkers to cutaneous clinical score (CLASI) outcomes.
Presented by Servier and Rosa at the Population Approach Group in Europe (PAGE) meeting, September 2021
Reuse of a published model to support compassionate use of novel drug formulation for a rare disorder
Presented by Acer Therapeutics and Rosa at the American Society of Clinical Oncology (ASCO), June 2021
FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meeting report, summary of challenges/gaps, and future perspective
Published in AAPS Journal, Apr. 30, 2021